BioSpace News Archive

Cadent Therapeutics announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the 5th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:00 am ET in New York City.

Nephros, Inc. (Nasdaq: NEPH), a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets, will visit the Nasdaq MarketSite in Times Square

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed by its subsidiary Eidos Therapeutics (NASDAQ

RLDatix, a leading provider of governance, risk and compliance (GRC) solutions that drive patient safety, quality improvement and harm reduction in healthcare, today demonstrated its continued commitment to risk management and patient safety by announcing its participation in numerous events at the American Society for Health Care Risk Management’s (ASHRM) annual conference

PetMed Express, Inc. will announce its financial results for the quarter ended September 30, 2019 on Monday, October 21, 2019 at 8:00 A.M. Eastern Time, then at 8:30 A.M. Eastern Time, Menderes Akdag, the Company’s Chief Executive Officer and President, will host a conference call to review the financial results..

Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that it has entered into an Intellectual Property License Agreement (the “Agreement”) with Dartmouth College for an exclusive world-wide license of Intellectual Property related to 3D printable materials in the fields of human and animal health.

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CEO, David Giljohann, PhD, will present clinical data from the company’s Phase 1 study of its drug candidate XCUR17 in psoriasis.

ZyVersa is developing differentiated therapeutic options to meet the significant unmet medical needs of patients with kidney disease through two novel drug development platforms

Chardan Healthcare Acquisition Corp. (NYSE: CHAC, “CHAC”), a special purpose acquisition company (“SPAC”) sponsored by affiliates of Chardan Capital Markets LLC (“Chardan”) and BiomX Ltd. (“BiomX”), a microbiome company developing both natural and engineered phage therapies, announced that they entered into an amendment to their definitive agreement

BIONIK Laboratories Corp. (OTCQB:BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced it has partnered with Intelliware Development to meet the data connectivity needs of hospitals and healthcare facilities utilizing sensored technologies nationwide.